Patheon

More from Patheon

Gildess Packaging / Image: FiercePharma

1.3 Million Birth Control Pills Recalled

Endo recalls 162 lots of subpotent birth control pills manufactured by Patheon.

Patheon sells clinical packaging business to Bellwyck

Patheon Inc., a leading provider of contract development and manufacturing services to the global pharmaceutical industry, announced today that it has sold its global secondary clinical packaging and clinical distribution services business to Bellwyck Packaging Solutions, a private company with 20 years experience providing clinical trial and contract services for secondary packaging.

Patheon Announces a Change to its PDS Management Structure

Patheon Inc., a leading provider of contract development and manufacturing services to the global pharmaceutical industry, announced today that Mark J.

Patheon Forms "Patheon Certified Consultants" Service

Patheon, the world¹s leading global provider of contract development and manufacturing services, announced today the formation of Patheon Certified Consultants, a new consulting capability comprised of industry veterans who provide a unique service to emerging biotech and pharmaceutical companies, as well as their investors, to help address early-, mid- and late-stage CMC questions in drug development•€¹from strategic to practical.

Patheon Adds Soft Gel Capsule Capabilities Through New Partnership with Procaps, S.A. (now United Caps)

Patheon and PROCAPS S.A. are pleased to announce an agreement to provide the pharmaceutical industry a new world-class line of prescription pharmaceutical soft-gel product development and manufacturing services.

Patheon announces change to its Board of Directors

Patheon Inc. (TSX: PTI), a leading provider of contract development and manufacturing services to the global pharmaceutical industry, is pleased to announce the appointment of Michel Lagarde, Principal, JLL Partners, to its Board of Directors.

Patheon signs three year $18 million development agreement with Boehringer Ingelheim

Patheon, Inc. (TSX: PTI), a global provider of drug development and manufacturing services to the international pharmaceutical industry announced today that Boehringer Ingelheim, a leading globally operating pharmaceutical corporation, has awarded it two projects with combined revenue of more than $18 million over a three year period of time.